EUVIMEDOpdag EUVIMED
Open access

Prenatal diethylstilbestrol exposure and risk of benign breast disease: The National Cancer Institute Diethylstilbestrol Follow‐up Study

Paloma R Mitra iD, Kimberly A Bertrand iD, Ruth M Pfeiffer iD, Julie R Palmer, Soumya Ramireddy, Marianne Hyer, Shaoqi Fan iD, William C Strohsnitter, Kjersti M Aagaard, Dezheng Huo, Linda Titus, Rebecca Troisi iD and 1 more

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70331 ↗

At a glance

Journal article in International Journal of Cancer, 2026. Written by Paloma R Mitra and 12 co-authors. Institution: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA. Major MEDLINE topics: Diethylstilbestrol, Prenatal Exposure Delayed Effects, Breast Diseases, Estrogens, Non-Steroidal. 39 references. The full text is freely available in PubMed Central. Funded by: Intramural NIH HHS, NCI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Prenatal exposure to diethylstilbestrol (DES), a prototypical endocrine disruptor, has been associated with increased breast cancer risk after age 40. We assessed the association between prenatal DES exposure and self‐reported benign breast disease (BBD)—an established breast cancer risk factor—among 4208 DES‐exposed and 1830 unexposed women in the National Cancer Institute DES Follow‐up Study. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Follow‐up started at birth and ended at the earliest of: BBD, breast cancer diagnosis, death, or loss to follow‐up. We estimated cumulative incidence of BBD by DES exposure. Over the course of the study, 6038 women contributed 333,458 person‐years with median follow‐up of 43.0 (range: 13.8–74.0) years for 1089 BBD cases and 60.0 (range: 19.7–80.3) years for 4949 non‐cases. Comparing BBD rates among DES‐exposed with unexposed women, the HR was 0.97 (95% CI: 0.84, 1.11), with no evidence of a dose–response relationship or difference in cumulative incidence by exposure. In conclusion, the HR for BBD was not elevated among women who were prenatally exposed to DES, suggesting that observed increases in breast cancer risk associated with DES are not due to this pathological mechanism.

Subjects

MeSH terms (MEDLINE)

DiethylstilbestrolPrenatal Exposure Delayed EffectsBreast DiseasesEstrogens, Non-SteroidalFemaleHumansFollow-Up StudiesPregnancyUnited StatesAdultMiddle AgedRisk FactorsNational Cancer Institute (U.S.)Breast NeoplasmsAgedIncidenceProportional Hazards Models

Author keywords

benign breast diseasediethylstilbestrolendocrine disruptorepidemiologyprenatal exposure

Substances

DiethylstilbestrolEstrogens, Non-Steroidal

Authors and institutions

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Slone Epidemiology Center, Boston University, Boston, Massachusetts, USA.
  • Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Information Management Services, Inc., Rockville, Maryland, USA.
  • Department of Molecular, Cell, and Cancer Biology, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.

ORCID profiles: Paloma R Mitra, Kimberly A Bertrand, Ruth M Pfeiffer, Shaoqi Fan, Rebecca Troisi, Gretchen L Gierach

Funding

  • Intramural NIH HHS
  • NCI NIH HHS

Cite

APA

Mitra, P. R., Bertrand, K. A., Pfeiffer, R. M., Palmer, J. R., Ramireddy, S., Hyer, M., Fan, S., Strohsnitter, W. C., Aagaard, K. M., Huo, D., Titus, L., Troisi, R., & Gierach, G. L. (2026). Prenatal diethylstilbestrol exposure and risk of benign breast disease: The National Cancer Institute Diethylstilbestrol Follow‐up Study. International Journal of Cancer. https://doi.org/10.1002/ijc.70331

Vancouver

Mitra PR, Bertrand KA, Pfeiffer RM, Palmer JR, Ramireddy S, Hyer M, et al. Prenatal diethylstilbestrol exposure and risk of benign breast disease: The National Cancer Institute Diethylstilbestrol Follow‐up Study. International Journal of Cancer. 2026. doi:10.1002/ijc.70331

BibTeX
@article{Mitra2026,
  author = {Mitra, Paloma R and Bertrand, Kimberly A and Pfeiffer, Ruth M and Palmer, Julie R and Ramireddy, Soumya and Hyer, Marianne and Fan, Shaoqi and Strohsnitter, William C and Aagaard, Kjersti M and Huo, Dezheng and Titus, Linda and Troisi, Rebecca and Gierach, Gretchen L},
  title = {Prenatal diethylstilbestrol exposure and risk of benign breast disease: The National Cancer Institute Diethylstilbestrol Follow‐up Study},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70331}
}
Start for free →